Hana Malikova MD, Presenter: Nothing to Disclose

Roman Liscak PhD, Abstract Co-Author: Nothing to Disclose

Zdenek Vojtech MD, Abstract Co-Author: Nothing to Disclose

Josef Vymazal MD, PhD, Abstract Co-Author: Consultant, EPIX Pharmaceuticals, Inc, Boston, MA Consultant, NovoCure Ltd, Haifa, Israel

Tomas Prochazka MD, Abstract Co-Author: Nothing to Disclose

Stereotactic radiofrequency amygdalohippocampectomy (AHE) has been reintroduced as an alternative treatment of mesial temporal lobe epilepsy. The aim of this study was to describe MRI changes after stereotactic AHE and to correlate hippocampal volume reduction with the clinical outcome.

Eighteen patients, who underwent stereotactic AHE, were included. Hippocampal volumetry was calculated from preoperative MRI and from MRI obtained 1 year after the operation. The clinical outcome was examined 1 and 2 years after the treatment.

Fourteen patients had left-sided and 4 patients right-sided operation. Hippocampal volume decreased by 54±18%. One year after the procedure, 13 (72%) patients were classified as Engel’s Class I, 4 (22%) patients as Class II and 1 (6%) patient as Class III. Two years after the operation, 14 patients (82%) were classified as Class I and 3 patients (18%) as Class II. Clinical effect Engel´s Class IA occurred in 67% of patients with above-median hippocampal reduction, while only in 33% of patients with below-median reduction.

 Volume reduction of target structures after AHE is significantly related to clinical outcome.

Radiofrequency AHE is a minimally invasive method with promising clinical results. 

Malikova, H, Liscak, R, Vojtech, Z, Vymazal, J, Prochazka, T, Stereotactic Radiofrequency Amygdalohippocampectomy for the Treatment of Temporal Lobe Epilepsy: Correlation of MRI Volumometry with Clinical Seizure Outcome.  Radiological Society of North America 2008 Scientific Assembly and Annual Meeting, February 18 - February 20, 2008 ,Chicago IL. http://archive.rsna.org/2008/6014554.html